The Cannigma Weekly Roundup: Sepember 14th, 2026

by joe

Hello and welcome back to our new roundup, which from today will be settled into it’s proper weekly cadence. In this week’s edition: a federal appeals court cleared the path for cannabis rescheduling to continue, while product safety concerns dominated state-level headlines and the UK moved closer to formally authorising CBD as a food ingredient for the first time.

United States

Federal Court Rejects Bid to Block Cannabis Rescheduling

A federal appeals court this week denied an emergency request from a drug testing industry association and a pharmaceutical company to halt the Trump administration’s cannabis rescheduling process while their legal challenge proceeds. The court found that petitioners had not met the standard required for a stay, allowing the rescheduling process to move forward. The ruling is a significant procedural win for the administration, though the underlying litigation remains ongoing.

The Cannigma’s Take: Congress briefly tried to intervene too – a House appropriations panel voted to cut off rescheduling funds – but insiders say that effort is likely to fail. In practical terms, both political branches are testing the waters, but the courts have now cleared the way for regulators to proceed.

DEA Rescheduling Compliance Creates Friction for Dispensary Operators

Even as rescheduling advances, implementation is generating new conflicts. A medical marijuana dispensary owner in Mississippi says the DEA is requiring her to dismiss two employees as a condition of registering for federal protections under the rescheduling framework. She has said she plans to fight the decision. The case illustrates how the practical mechanics of rescheduling are creating compliance burdens that were not widely anticipated when the policy shift was announced.

The Cannigma’s Take: This Mississippi case highlights a predictable clash where state‐legal cannabis shops are now being pushed under long‐standing federal rules. The DEA is simply enforcing the old CSA requirement that registered dispensaries can’t have convicted felons on staff. That rule has existed for decades in pharmacy law, but few state‐licensed pot shops ever faced it until now.

House Majority Leader Calls Cannabis a “Gateway Drug”

House Majority Leader Steve Scalise (R-LA) told Marijuana Moment that he believes marijuana is a gateway drug and expressed concern about the Trump administration’s rescheduling move. The statement puts one of the most powerful Republicans in Congress at odds with the administration’s own policy direction, and signals that legislative action to codify or expand rescheduling could face resistance from GOP leadership even as the executive branch presses ahead.

The Cannigma’s Take: Scalise’s blunt gateway‐drug claim gives another example of how some congressional leaders are completely at odds with the administration’s reform momentum. It makes clear that even if the Justice Department pushes rescheduling forward, Republican lawmakers at the top remain deeply skeptical.

Federal Report: States Earned Over $15 Billion in Cannabis Tax Revenue Over Five Years

A newly updated U.S. Census Bureau report found that states have collectively generated more than $15 billion in marijuana tax revenue since the agency began tracking the data in the third quarter of 2021, with over $3.5 billion collected in the past year alone. The federal government’s own data now formally documents the fiscal scale of state cannabis markets, a detail that advocates say strengthens the case for federal reform. The report lands as Massachusetts separately announced it has surpassed $10 billion in adult-use sales since its market opened in 2018.

The Cannigma’s Take: The new Census Bureau report underscores what state budgets have known for years… that legal cannabis markets are now big business. This undeniably strengthens advocates’ arguments for reform has tangible payoffs. Economists will note that such amounts could easily sway fence‐sitting lawmakers if they’re paying attention to the numbers.

Ohio Dispensary Closes After Adverse Health Reports Linked to Vapes

An Ohio marijuana dispensary closed this week following reports of adverse health effects in customers who purchased vape products there. Officials noted that a death occurred at a local emergency room during the relevant time period, though authorities said it is not yet known whether the death is connected to the cannabis products. The incident echoes concerns raised separately this week about Colorado regulators being criticised for slow public notification when similar adverse-effect reports emerged in that state, pointing to a broader pattern of questions about product safety oversight across legal markets.

The Cannigma’s Take: Regulators will note that all affected products came from a single dispensary brand. If the outbreak is traced to a specific faulty product, it highlights the importance of supply-chain integrity. The bigger lesson: states may need clearer emergency rules to rapidly investigate and alert the public.

Massachusetts Faces Ballot Measure That Would Roll Back Legalization

Massachusetts voters will soon weigh in on Question 8, a ballot measure that would significantly curtail the state’s adult-use cannabis market. The measure arrives as the state’s Cannabis Control Commission announced the $10 billion sales milestone, and industry advocates have argued that eliminating licensed retailers would push consumers toward unregulated channels without eliminating demand. The outcome of the vote could make Massachusetts the first state to substantially reverse recreational legalization through a popular ballot measure.

The Cannigma’s Take: A vivid reminder that legalization can meet backlash even in established markets. Advocates note MA’s industry has generated ~$1.5B in taxes and 27,000 jobs so far, but opponents are pushing hard on public health fears. If voters repeal the system, Massachusetts would become the first state to dismantle its legal market by referendum.

Illinois Approves Biggest Medical Cannabis Market Expansion in a Decade

Illinois regulators approved new medical cannabis licenses for 37 existing adult-use dispensaries, allowing them to also serve registered medical patients. Officials described it as the largest expansion of the state’s medical market in ten years, stemming from omnibus cannabis legislation signed into law by the governor. The move is intended to improve patient access and integrate the state’s dual-track cannabis system more efficiently.

The Cannigma’s Take: By letting 37 existing adult‐use dispensaries serve medical patients, Illinois is effectively merging its two-track system. Regulators say this change will significantly improve access and cut unnecessary red tape. In context, it matches moves in other states (like Maryland and Virginia) to unify recreational and medical markets for efficiency and patient convenience.

Wisconsin Congressman Says Legalization Could Come in 2027

A Democratic congressman from Wisconsin said this week that the state is positioned to legalise marijuana as early as 2027, with or without a Democratic majority in the legislature, citing shifting attitudes among some Republicans under potential new leadership. The claim is notable given that Wisconsin remains one of the few Midwestern states without any form of legal cannabis, and that NORML data published this week showed Wisconsin is among six states where more than half of all drug arrests are for marijuana.

The Cannigma’s Take: Rep. Pocan is signaling that a switch in leadership (Assembly Speaker Robin Vos is retiring) could open the door for change. In fact, Wisconsin’s new Majority Leader recently said it’s “time to modernize” cannabis policy. With both parties recognizing that nine neighboring states have legal weed, the politics may finally be shifting.

Europe and UK

UK FSA Recommends First-Ever CBD Food Authorisations

The UK Food Standards Agency (FSA) this week recommended three CBD novel food applications for ministerial approval, a move that could bring an estimated 3,000 products into legal compliance and make Britain one of the first countries in the world to formally authorise CBD as a food ingredient. The development is significant for an industry that has operated in regulatory limbo since the novel food framework was applied to CBD products. However, the FSA’s own board paper flagged that a post-Brexit trade arrangement could potentially override the domestic authorisation process, introducing uncertainty about whether the approvals will hold.

The Cannigma’s Take: If approved, Britain will become the world’s first country to formally authorize CBD as a novel food.. In practice, this would move a huge portion of the UK’s CBD industry from regulatory limbo into compliance, a step that could lead to consumer confidence (and likely boost sales) in a previously murky market.

French Trade Groups Fight CBD Crackdown Ahead of Key Ruling

In France, industry trade groups are preparing for a pivotal legal ruling after the Council of State rejected their initial attempt to block a government crackdown on CBD products. The Ministry of Agriculture and Food Sovereignty raised safety concerns earlier this year that underpinned the restrictions. Trade group representatives said they remain confident ahead of the next ruling, but the case underscores the divergence between France’s approach and the direction the UK FSA moved this week.

The Cannigma’s Take: France’s crackdown could be derailed by the same court that overturned the CBD flower ban in 2022. Industry lawyers see history repeating: in 2022 the Conseil d’État struck down a prior ban as unlawful, and they’re banking on a similar outcome this time.

Rest of World

Brazil Cannabis Medicine Imports Surge as Market Expands

Brazil’s National Health Surveillance Agency (Anvisa) recorded another sharp increase in import approvals for cannabis medicines this week, adding to evidence that hemp-derived CBD is becoming an established part of the country’s medical market. Regulators have been building a more defined approval pathway for these products, and the continued growth in import volumes suggests demand is outpacing domestic supply. Brazil’s trajectory stands in contrast to more restrictive approaches seen elsewhere in Latin America.

The Cannigma’s Take: Brazil’s medical program is booming – massive growth that is far above anything seen in most of Latin America. In effect, Brazil’s demand is outstripping its own production, forcing patients to turn to imports en masse.

Curaleaf and Aurora Cannabis Takeover Battle Intensifies

The ongoing takeover bid by U.S. multi-state operator Curaleaf for Canadian cannabis company Aurora has escalated into a public dispute over financial projections, proposed governance structures, and whether the deal can close on its current terms. As reported in earlier coverage, the bid has been contested since it was announced; this week the disagreement became more pointed, with both sides publicly challenging the other’s valuations and characterisations of the proposed entity’s control structure.

The Cannigma’s Take: This is a corporate clash unprecedented in recent cannabis history. Each side is publicly calling the other’s figures dishonest. The raw tone and tepid mid‐deal negotiation (with CEOs airing grievances on social media) underscores how divided the two camps are.

Contradictions and Tensions

More tensions highlighted this week at the heart of federal cannabis policy. A federal appeals court allowed rescheduling to proceed, and the Census Bureau published data showing states have earned more than $15 billion in cannabis tax revenue, yet House Majority Leader Steve Scalise simultaneously called cannabis a gateway drug and signalled scepticism about the administration’s direction. The executive branch is pushing rescheduling forward while one of the most powerful figures in the legislative branch is publicly opposed, and the DEA’s compliance demands on Mississippi dispensary operators suggest that even within the executive branch, implementation is generating friction rather than clarity.

The product safety stories from Ohio and Colorado also sit uneasily alongside the broader pro-legalisation argument that regulated markets produce safer products. Advocates have argued that legal frameworks protect consumers, but reports of adverse health effects in licensed dispensary customers, combined with criticism of slow regulatory notification in Colorado, complicate that case. This tension is directly acknowledged in an op-ed published this week by Americans for Safe Access, which argued that the legalisation movement should treat safety problems as issues to be solved rather than suppressed.